BUZZ - India's Kotak Mahindra Bank shares rise on second quarter loan growth; Goldman Sachs reiterates 'Buy' rating

In the first paragraph, stock information was added. Paragraphs 2 to 8 provide a detailed introduction to the disease and the clinical trial situation. Reuters, Oct. 6 - ArriVent BioPharma (AVBP.O) said on Tuesday that its oral therapy for treating rare lung cancer failed to meet its primary goal of delaying disease progression in a late-stage clinical trial, leading to its shares plunging by 63% in premarket trading. The therapy, firmonertinib, targets previously untreated advanced non-small cell lung cancer (NSCLC) patients who carry a gene mutation called the EGFR exon 20 insertion, which can promote cancer growth. This mutation accounts for about 0.5% to 1% of all NSCLC cases. NSCLC represents about 85% of all lung cancer cases. In the trial, according to independent reviewers, the 240mg dosage developed by ArriVent extended median progression-free survival to 11 months, compared to 9.5 months in the chemotherapy group. Chief Executive Officer Bing Yao stated that the improvement in progression-free survival (defined as the length of time patients live without worsening or spread of disease) was not significant. "These disappointing results are not what we had hoped for, especially for patients with EGFR exon 20 insertion-mutant NSCLC who are in urgent need of more effective treatments," said Yao. The company is evaluating the full data set to determine the most suitable development path for firmonertinib. ArriVent stated that no new safety signals were observed in the trial. The therapy has already been approved in China for non-small cell lung cancer patients carrying specific mutations. (For the convenience of non-English language speakers, Reuters has automated the translation of its reporting into several other languages. Due to possible errors or missing context in automated translation, Reuters does not guarantee the accuracy of automated translated texts and provides them for readers’ convenience only. Reuters accepts no responsibility for any damages or losses caused by the use of the automated translation feature.)

09:15 AM EDT, 10/06/2026 (MT Newswires) -- Consumer stocks were edging higher premarket Tuesday, with the State Street Consumer Staples Select Sector SPDR ETF (XLP) up 0.1% and the State Street Consumer Discretionary Select Sector SPDR ETF (XLY) advancing by 0.4%. Nomad Foods (NOMD) stock was up nearly 3% after the company said it now expects fiscal 2026 organic revenue to decline 2% to 3%, compared with its previous guidance for a decline of 2% to 5%. PepsiCo (PEP) and Monster Beverage (MNST) can continue to label their cans in India as energy drinks after a court ruling, Reuters reported, citing a lawyer present at the hearing. PepsiCo shares were slightly higher and Monster Beverage stock was down 0.3% pre-bell. B&G Foods (BGS) said it cancelled its agreement to sell Green Giant Canada to Nortera Foods on Monday, after failing to obtain Canadian regulatory approval. Shares of B&G Foods were up more than 1% premarket.

09:04 AM EDT, 10/06/2026 (MT Newswires) -- (Updates with pricing details in the headline and the first paragraph; and the offering close date in the last paragraph.) TORM (TRMD) said Tuesday that OCM Njord, a company indirectly owned by funds managed by Oaktree Capital Management and its affiliates, priced a secondary offering of 6.3 million class A shares for gross proceeds of about $253.5 million. The company said OCM Njord owns about 6% of its class A shares before the offering. TORM is not selling any shares and will not receive proceeds from the offering, the company said. The offering is expected to close on Wednesday, TORM said.

NexPoint Residential Trust schedules a third-quarter 2026 earnings conference call for Nov. 3, 2026 at 11:00 a.m. ET. Third-quarter 2026 results release set for before the market open on Nov. 3, 2026. Live webcast planned on https://nxrt.nexpoint.com; replay expected to remain available for 60 days. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NexPoint Residential Trust Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610060900PR_NEWS_USPR_____NY63815) on October 06, 2026, and is solely responsible for the information contained therein.